Hyundai Bioscience Co., Ltd.
048410.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$668.77B
Close$
$-284.60
104.3% downside
Current Fair Value
104.3% downsideOvervalued by 104.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $668.77 Billion |
|---|---|
| Enterprise Value | $674.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-230.41 |
| Beta | 0.77 |
| Outstanding Shares | 96,141,951 |
Return
| Return on Equity | -25.62% |
|---|---|
| Return on Assets | -20.15% |
| Return on Invested Capital | -17.08% |
Valuation & Multiples
| P/E Ratio | -25.16 |
|---|---|
| PEG | -20.77 |
| Price to Sales | 196.76 |
| Price to Book Ratio | 6.23 |
| Enterprise Value to Revenue | 203.11 |
| Enterprise Value to EBIT | -35.01 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hyundai Bioscience Co., Ltd.
54 employees
CEO: Jong-Won Choi Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a ...